Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 23

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 23
---
 align='center'>-15-</div>

#### Audit Committee
The members of our audit committee are detailed in the table above. All members of our audit committee meet the requirements for independence and financial literacy of audit committee members under Nasdaq listing standards and SEC rules and regulations. Our audit committee chairperson, Mr. Klein, is our audit committee financial expert, as that term is defined under the SEC rules implementing Section 407 of the Sarbanes-Oxley Act of 2002, and possesses financial sophistication, as defined under Nasdaq listing standards. Effective as of the Annual Meeting, Mr. Krognes will join our audit committee. Mr. Krognes will meet the requirements for independence of audit committee members under Nasdaq listing standards and SEC rules and regulations on May 1, 2025, three years after he ceased serving as our Chief Financial Officer. Mr. Krognes also meets the requirements for financial literacy of audit committee members under the Nasdaq listing standards and SEC rules and regulations.

The responsibilities of our audit committee include, among other things:

• selecting and hiring the independent registered public accounting firm to audit our financial statements;

• helping to ensure the independence and performance of the independent registered public accounting firm;

• pre-approving all audit and non-audit services and fees;

• reviewing financial statements and discussing with management and the independent registered public accounting firm our annual audited and quarterly consolidated financial statements, the results of the independent audit and the quarterly reviews, and the reports and certifications regarding internal controls over financial reporting and disclosure controls;

• preparing the audit committee report that the SEC requires to be included in our annual proxy statement;

• reviewing reports and communications from the independent registered public accounting firm;

• reviewing the adequacy and effectiveness of our internal controls and disclosure controls and procedures;

• reviewing our policies on risk assessment and risk management, including risk concerning information security;

• reviewing related party transactions; and

• establishing and overseeing procedures for the receipt, retention and treatment of accounting related complaints and the confidential submission by our employees of concerns regarding questionable accounting or auditing matters.

Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and Nasdaq listing requirements. A copy of the charter of our audit committee is available on our website at https://denalitherapeutics.com/investors in the Corporate Governance section of our Investor & Media Relations web page.

<div align='center'>-16-</div>

#### Compensation Committee
The members of our compensation committee are detailed in the table above. All members